Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.370
Sell
RSI(14)
35.406
Neutral
STOCH(KDJ)(9,3,3)
29.359
Neutral
ATR(14)
1.078
Low Volatility
CCI(14)
-82.969
Neutral
Williams %R
79.259
Sell
TRIX(12,20)
-0.612
Sell
StochRSI(14)
99.168
Buy
Teva Pharmaceutical Industries Ltd
TEVA29.810USD
+1.040+3.61%
Market hours （ET）Quotes delayed by 15 min
34.28BMarket Cap
24.21P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Teva Pharmaceutical Industries Ltd
Currency: USD Updated: 2026-03-24Key Insights
Teva Pharmaceutical Industries Ltd's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 45 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 38.35.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Teva Pharmaceutical Industries Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative-
Teva Pharmaceutical Industries Ltd Highlights
StrengthsRisks
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 23.66, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 665.23M shares, decreasing 17.10% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 12.75K shares of this stock.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
38.355
Target Price
+33.50%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-24The current financial score of Teva Pharmaceutical Industries Ltd is 8.60, ranking 40 out of 157 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 4.72B, representing a year-over-year increase of 11.73%, while its net profit experienced a year-over-year increase of 321.20%.
Score
Financials
5.51
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
9.80
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.69
Teva Pharmaceutical Industries Ltd's Company Valuation
Currency: USD Updated: 2026-03-24The current valuation score of Teva Pharmaceutical Industries Ltd is 5.79, ranking 139 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 23.66, which is 122.71% below the recent high of 52.70 and 838.71% above the recent low of -174.80.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 45/157
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-24The current earnings forecast score of Teva Pharmaceutical Industries Ltd is 8.46, ranking 33 out of 157 in the Pharmaceuticals industry. The average price target is 29.50, with a high of 35.00 and a low of 18.07.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
38.355
Target Price
+33.50%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
Teva Pharmaceutical Industries Ltd
TEVA
13
Biogen Inc
BIIB
37
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
35
Vertex Pharmaceuticals Inc
VRTX
34
Gilead Sciences Inc
GILD
33
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-24The current price momentum score of Teva Pharmaceutical Industries Ltd is 6.78, ranking 57 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 32.79 and the support level at 26.89, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
29.138
Buy
MA10
29.358
Buy
MA20
30.981
Sell
MA50
32.501
Sell
MA100
29.987
Sell
MA200
23.959
Buy
Institutional Confidence
Currency: USD Updated: 2026-03-24The current institutional shareholding score of Teva Pharmaceutical Industries Ltd is 5.00, ranking 72 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 57.84%, representing a quarter-over-quarter decrease of 10.61%. The largest institutional shareholder is Larry Robbins, holding a total of 16.72M shares, representing 1.44% of shares outstanding, with 11.42% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-03-24The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Teva Pharmaceutical Industries Ltd is 7.54, ranking 36 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.79. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.79
VaR
+3.36%
240-Day Maximum Drawdown
+21.19%
240-Day Volatility
+39.63%
Return
Best Daily Return
60 days
+4.23%
120 days
+20.23%
5 years
+28.37%
Worst Daily Return
60 days
-4.41%
120 days
-4.41%
5 years
-13.89%
Sharpe Ratio
60 days
-1.02
120 days
+2.34
5 years
+0.66
Risk Assessment
Maximum Drawdown
240 days
+21.19%
3 years
+43.70%
5 years
+43.70%
Return-to-Drawdown Ratio
240 days
+5.40
3 years
+1.68
5 years
+0.74
Skewness
240 days
+1.64
3 years
+2.13
5 years
+2.14
Volatility
Realised Volatility
240 days
+39.63%
5 years
+40.89%
Standardised True Range
240 days
+2.48%
5 years
+1.54%
Downside Risk-Adjusted Return
120 days
+561.38%
240 days
+561.38%
Maximum Daily Upside Volatility
60 days
+25.17%
Maximum Daily Downside Volatility
60 days
+24.99%
Liquidity
Average Turnover Rate
60 days
+0.99%
120 days
+1.04%
5 years
--
Turnover Deviation
20 days
+7.82%
60 days
+10.69%
120 days
+16.03%
Peer Comparison
Pharmaceuticals
Teva Pharmaceutical Industries Ltd
TEVA
7.32 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.83 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
8.43 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ligand Pharmaceuticals Inc
LGND
8.33 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.32 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
